Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis-Reference-Cited by-同舟云学术

Talabostat, fibroblast activation protein inhibitor, attenuates inflammation and fibrosis in systemic sclerosis

Published:2024-08-21 Issue: Volume: Page:
ISSN:0925-4692
Container-title:Inflammopharmacology
language:en
Short-container-title:Inflammopharmacol

Author:

Pashaei Mehrnoosh^ORCID,Farhadi Elham^ORCID,Kavosi Hoda^ORCID,Madreseh Elham^ORCID,Enayati Samaneh^ORCID,Mahmoudi Mahdi^ORCID,Amirzargar Aliakbar^ORCID

Funder

Tehran University of Medical Sciences and Health Services

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10787-024-01536-6.pdf

Reference38 articles.

1. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, VARGA J (2015) Systemic sclerosis. Nat Rev Dis Prim 1:1–21. https://doi.org/10.1038/nrdp.2015.2

2. Ayers NB, Sun CM, Chen SY (2018) Transforming growth factor-β signaling in systemic sclerosis. J Biomed Res 32:3–12. https://doi.org/10.7555/JBR.31.20170034

3. Barnes TC, Anderson ME, Moots RJ (2011) The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol. https://doi.org/10.1155/2011/721608

4. Dziankowska-Bartkowiak B, Zebrowska A, Joss-Wichman E, Kobos J, Waszczykowska E (2006) Expression of metalloproteinases and their inhibitors in skin lesions of systemic sclerosis {SSc) patients. Central Eur J Immunol 31:94

5. Egger C, Cannet C, Gérard C, Suply T, Ksiazek I, Jarman E, Beckmann N (2017) Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol 809:64–72. https://doi.org/10.1016/j.ejphar.2017.05.022